Specifically for ARPKD, strategies like antisense oligonucleotide therapy targeting c-myc and CRISPR/ Cas9 knockdown of the P2rx7 gene have shown promise. The gene discussed is MYC; the disease is autosomal recessive polycystic kidney disease.